Class Action Lawsuit Filed Against Integer Holdings Corporation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Integer Holdings Corporation on behalf of investors who purchased shares between July 25, 2024, and October 22, 2025, alleging that the company materially overstated its competitive position in the EP manufacturing market.
- Allegation Details: The complaint claims that despite the company's assertions of strong visibility into customer demand, it was experiencing a sustained decline in sales of two EP devices, misleadingly characterizing them as long-term growth drivers for its C&V segment.
- Investor Rights: Affected investors must apply by February 9, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering free consultations to those seeking more information about their legal rights and options.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, boasting extensive litigation experience and a nationwide practice.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 86.230
Low
75.00
Averages
93.38
High
140.00
Current: 86.230
Low
75.00
Averages
93.38
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
